GENE THERAPY FOR DIABETIC ISCHEMIC DISEASE

(19)

(11)

EP 1 142 590 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	26.11.2008 Bulletin 2008/48

(45)	Mention of the grant of the patent:
	01.10.2008 Bulletin 2008/40

(21)	Application number: 00971697.8

(22)	Date of filing: 26.10.2000

(51)

International Patent Classification (IPC):

A61K 48/00^(2006.01)
A61K 9/127^(2006.01)
A61P 3/10^(2006.01)

A61K 38/22^(2006.01)
A61P 9/10^(2006.01)

(86)	International application number:
	PCT/JP2000/007502

(87)	International publication number:
	WO 2001/032220 (10.05.2001 Gazette 2001/19)

(54)	GENE THERAPY FOR DIABETIC ISCHEMIC DISEASE GENTHERAPIE FÜR DIABETISCHE ISCHÄMIE THERAPIE GENIQUE POUR TRAITER LES MALADIES ISCHEMIQUES DIABETIQUES

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30)

Priority:

29.10.1999 JP 30998499

(43)	Date of publication of application:
	10.10.2001 Bulletin 2001/41

(73)	Proprietor: AnGes MG, Inc.
	Ibaraki-shi, Osaka (JP)

(72)	Inventors:
	MORISHITA, Ryuichi Osaka 565-0851 (JP) OGIHARA, Toshio Minoo-shi, Osaka 562-0046 (JP)

(74)	Representative: Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät
	Leopoldstrasse 4 80802 München 80802 München (DE)

(56)

References cited: :

WO-A-00/62798
WO-A-98/51798
WO-A1-97/14307

WO-A-98/19712
WO-A-99/36103
WO-A1-99/36103

UEDA HIDEKI ET AL: "In vivo gene transfection of hepatocyte growth factor attenuates ischemia-reperfusion injury in the heart: Evidence for a role of HGF in endogenous myocardial protection" CIRCULATION, vol. 96, no. 8 SUPPL., 1998, page I619, XP002935421 & 70TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION; ORLANDO, FLORIDA, USA; NOVEMBER 9-12, 1997 ISSN: 0009-7322
AOKI MOTOKUNI ET AL: "Beneficial angiogenesis induced by over-expression of human hepatocyte growth factor (HGF) in non-infarcted and infarcted myocardium: Potential gene therapy for myocardial infarction" CIRCULATION, vol. 98, no. 17 SUPPL., 27 October 1998 (1998-10-27), page I321, XP002936330 & 71ST SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION; DALLAS, TEXAS, USA; NOVEMBER 8-11, 1998 ISSN: 0009-7322
MORISHITA R ET AL: "Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy ." HYPERTENSION, (1999 JUN) 33 (6) 1379-84. JOURNAL CODE: 7906255. ISSN: 0194-911X., June 1999 (1999-06), XP002308376
ERIC VAN BELLE ET AL.: 'Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor' CIRCULATION vol. 97, 1998, pages 381 - 390, XP002936327
GRAND D.S. ET AL.: 'Scatter factor induces blood vessel formation in vivo' PROC. NATL. ACAD. SCI. USA vol. 90, 1993, pages 1937 - 1941, XP002936328
AOKI MOTOKUNI ET AL.: 'Beneficial angiogenesis induced by over-expression of human hepatocyte growth factor (HGF) in non-infarcted and infarcted myocardium: Potential gene therapy for myocardial infarction' CIRCULATION vol. 98, no. 17, 1998, page I321, XP002936329
UEDA HIDEKI ET AL.: 'In vivo gene transfection of hepatocyte growth factor attenuates ischemia-reperfusion injury in the heart: Evidence for a role of HGF in endogenous myocardial protection' CIRCULATION vol. 96, no. 8, 1997, page I619, XP002936330

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).